Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 9/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | FURIN | P09958 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18822243 | 0.93 | SIRT2 (0.41) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL24220963 | 0.93 | SIRT2 (0.41) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL21728798 | 0.92 | SIRT2 (0.41) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL20750038 | 0.92 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL19372451 | 0.92 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL16202562 | 0.92 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL21901403 | 0.92 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL22541305 | 0.92 | SIRT2 (0.44) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL19485777 | 0.92 | SIRT2 (0.44) | SIRT2SIRT1SIRT3SIRT5HTT | |
| SCHEMBL15499771 | 0.92 | SIRT2 (0.42) | SIRT2SIRT1SIRT3SIRT5HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771775-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-10960083-B2 | Binding protein drug conjugates comprising anthracycline derivatives | NBE-THERAPEUTICS AG (CH) | 2021-03-30 | — | — | US | disclosed |
| EP-3610889-A1 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHOD FOR PREPARING THE SAME | LegoChem Biosciences, Inc. (KR) | 2020-02-19 | — | — | EP | disclosed |
| EP-2707031-B1 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHOD FOR PREPARING THE SAME | LEGOCHEM BIOSCIENCES INC (KR) | 2019-06-26 | — | — | EP | disclosed |
| US-20180127505-A1 | HUMANIZED ANTI-AXL ANTIBODIES AND THEIR CONJUGATES | ADC THERAPEUTICS SA (CH) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127505-A1 | HUMANIZED ANTI-AXL ANTIBODIES AND THEIR CONJUGATES | AXL, TYRO3, FLT3 | SIRT2 1493/4885SIRT1 1932/4885SIRT3 2528/4885 |
| US-11771775-B2 | Pyrrolobenzodiazepine-antibody conjugates | CD79B, BCL6B, BCL6 | SIRT2 3855/4885SIRT1 4283/4885SIRT3 4266/4885 |
| US-10960083-B2 | Binding protein drug conjugates comprising anthracycline derivatives | ABCC1, BCR, HNRNPU | SIRT2 2594/4885SIRT1 3694/4885SIRT3 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.